Aberrant expression of microRNA-155 (miR-155) has been identified in Acute Myeloid Leukemia (AML) and may be related to clinical outcome, however this still needs to be further characterized. Hu X. L. and Tang A. P. investigated the expression of miR-155 in bone marrow mononuclear cells (BMMNC) of 80 patients with AML and its clinical significance. Their findings were published in the Chinese Association of Pathophysiology’s Journal of Experimental Hematology.
- MiR-155 expression levels in the moderate prognostic group and poor prognostic group were significantly higher as compared with the favorable prognosis group (P<0.05, P<0.05）
- The expression level of miR-155 did not significantly correlate with the clinical features of patients
In conclusion, although there is only a small pool of patients, overexpression of miR-155 correlated to poor prognosis in AML. However, no relationship between the levels of miR-155 and clinical features of AML was observed.
To investigate the expression of microRNA-155(miR-155) in bone marrow mononuclear cells (BMMNC) of the patients with acute myeloid leukemia (AML) and its clinical significance.
Real-time quantitative PCR (qPCR) was used to detect the expression level of miR-155 in bone marrow mononuclear cells from 80 cases of AML and 11 cases of negative control patients.
Compared with the negative control group, the expressions of miR-155 in initial diagnosis group and remission group both increased (P<0.01), that in the initial treatment group was significantly higher than the remission group (P<0.05). The expression level of miR-155 did not significantly correlate with the clinical features of patients. Between different cytogenetic groups in AML patients, miR-155 expression levels in the moderate prognostic group and poor prognostic group were significantly higher as compared with the favorable prognosis group P<0.05, P<0.05）, but there was no significant difference between poor and moderate prognostic groups(P>0.05). The results of tracking the situation after induction therapy of newly diagnosed AML patients showed that the remission rate of initial induction in miRNA155 high expression group and low expression group were 59.09% and 87.5% (X2 =4.8, P<0.05), and the expression level of miR-155 in initial diagnosis of patients without complete remission after chemotherapy was significantly higher than that in patients with complete remission after chemotherapy (P= 0.042).
The expression of miR-155 in AML patients is high and reduced the rate of complete remission. The high expression of miR-155 is a poor prognostic factor for patients with AML.